Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

Dermavant's phase 3 trials of tapinarof – PSOARING 1 and 2 – showed that around 40% of patients responded to treatment with clear or almost clear skin at 12 weeks, compared to 6% of a placebo ...

JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

becoming an alternative to corneal replacement using donor tiss Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama ...

Organon (NYSE: OGN) has recently announced its acquisition of Dermavant Sciences Ltd., a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. The ...

Dermavant was founded in 2015 as Roivant Dermatology Ltd. and changed its name the next year. The company has U.S. operations in Long Beach, California; Raleigh-Durham, North Carolina; Dallas and ...

The firm's positive stance comes after Roivant Sciences announced a significant deal to sell its Dermavant subsidiary to OGN for an estimated $1.2 billion in upfront and future milestone payments, in ...